year,risk_factors
2016,
2017,"Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Legal, Social and Political Risks"
2018,"Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Legal, Social and Political Risks"
2019," 
Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Legal, Social and Political Risks"
2020," 
Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Legal, Social and Political Risks"
2021,"The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.
Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. 
The COVID-19 pandemic has adversely impacted certain aspects of the Company’s business and could cause disruptions or future impact to the Company’s business, results of operations and financial condition.
Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
The Company faces significant regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
 
The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
The Company faces a variety of risks associated with conducting business internationally
Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Legal, Social and Political Risks
Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce. 
 
An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation.
Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations."
2022,"The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.
Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. 
The COVID-19 pandemic has adversely impacted certain aspects of the Company’s business and could cause disruptions or future impact to the Company’s business, results of operations and financial condition.
Global sales in the Company’s Pharmaceutical and Medical Devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
 
The Company faces increased challenges to intellectual property rights central to its business.
Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally
Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Financial, Economic, Legal, Social and Political Risks
Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
The planned separation of the Company’s Consumer Health business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.
The costs to complete the planned separation will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the planned separation of the Company’s Consumer Health business.
Following the planned separation, the price of shares of the Company’s common stock may fluctuate significantly.
The planned separation could result in substantial tax liability.
Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce. 
 
Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation.
A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact to the Company’s business or reputation."
2023,"The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.
Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. 
Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company’s business, results of operations and financial condition.
Global sales in the Company’s Pharmaceutical and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
 
The Company faces increased challenges to intellectual property rights central to its business.
Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally
Foreign Currency Exchange
Inflation and Currency Devaluation Risks
Illegal Importation of Pharmaceutical Products
Anti-Bribery and Other Regulations: 
Other Financial, Economic, Legal, Social and Political Risks
Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
The Russia-Ukraine War, and actions taken in response to the Russia-Ukraine War, could adversely affect our business, results of operations or financial condition.
The planned separation of the Company’s Consumer Health business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.
The costs to complete the planned separation will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the planned separation of the Company’s Consumer Health business.
Following the planned separation, the price of shares of the Company’s common stock may fluctuate significantly.
The planned separation could result in substantial tax liability.
Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce. 
 
Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation.
A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact to the Company’s business or reputation."
2024,"Foreign currency exchange
Inflation and currency devaluation risks
Illegal importation of pharmaceutical products
Anti-bribery and other regulations
Other financial, economic, legal, social and political risks"
